Fushine(SZ:300497) Huaxin Securities·2026-03-27 07:29Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Insights - The company is entering a profitable phase with new business ventures, significantly reversing previous losses [4]. - The revenue forecast for 2025 is projected at 1.185 billion yuan, with a net profit attributable to shareholders expected to be -53.07 million yuan. For Q1 2026, the net profit is anticipated to be between 52 million and 75 million yuan [4]. - The company has seen a turnaround in its new energy business, with significant price increases in key products leading to profitability [5]. - The pharmaceutical segment is benefiting from a decrease in raw material costs, improving gross margins [6]. - The approval of a new food ingredient, "Weiran Protein," opens new growth opportunities for the company [7]. Summary by Sections Business Performance - The new energy business (electrolyte additives VC/FEC) has transitioned from losses to profitability, with a gross margin improvement expected to exceed 50% in Q1 2026 due to price increases [5]. - The price of VC has risen from 110,000 yuan/ton to 220,000 yuan/ton, with current prices at 140,000 yuan/ton [5]. Pharmaceutical Segment - The price of the key raw material 6-APA has decreased from 320 yuan/kg in February 2025 to 180 yuan/kg in January 2026, leading to improved gross margins in the pharmaceutical business [6]. - Gross margins for the pharmaceutical manufacturing segment are projected to rise, with 2025 H1 margins already at 21% [6]. Growth Opportunities - The company’s product "Weiran Protein" has received approval as a new food ingredient, positioning it for entry into the artificial meat and health food markets [7]. - The company is accelerating the construction of a 20,000-ton capacity for microbial protein, having also obtained SELF-GRAS certification in the U.S. [7]. Financial Forecast - Revenue projections for 2025, 2026, and 2027 are 1.186 billion, 2.163 billion, and 2.364 billion yuan respectively, with EPS expected to improve from -0.09 to 1.16 yuan [9]. - The current stock price corresponds to a PE ratio of -195.8 for 2025, improving to 15.9 by 2027 [9].